|
|
||||||||
Department of Radiology and Nuclear Medicine, Research Institute for Tuberculosis and Cancer, Tohoku University
Department of Pharmacology, Research Institute for Tuberculosis and Cancer, Tohoku University
Cyclotron and Radioisotope Center, Tohoku University
Radioisotope Laboratory Section, Research Institute for Tuberculosis and Cancer, Tohoku University, Seiryocho, Japan
Division of Clinical Research, National Institute of Radiological Science, Chiba, Japan
Correspondence: For reprints contact: Kazuo Kubota, MD, PhD, Department of Radiology and Nuclear Medicine, Research Institute for Tuberculosis and Cancer, Tohoku University, 4-1 Seiryocho, Aoba-Ku, Sendai 980, Japan.
ABSTRACT
Positron labeled substrates such as sugars, amino acids, and nucleosides have been investigated for the in-vivo evaluation of biochemical processes in cancerous tissue. Hexosamines are obligatory structural components of many biologically important macromolecules, including membrane glycoproteins and mucopolysaccharide. We evaluated a new synthesized pharmaceutical, N-[18F]fluoroacetyl-D-glucosamine (18F-FAG), which is a structural analog of N-acetyl-D-glucosamine. C3H/HeMsNRS mice bearing spontaneous hepatomas were used for the tissue distribution study. At 60 min after injection, high uptakes were found in tumor (5.16, mean value of %dose/g), liver (3.71), and kidney (3.27). The tumor uptake of 18F-FAG showed the highest value in all tissues. In the PET study, VX-2 carcinoma of the rabbit was clearly visualized. Our preliminary results suggest that 18F-FAG has potential as a new agent for tumor imaging.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |